Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 233.82% from the stock’s previous close. A number of other equities […]
More Stories
Link Building: Meaning, Approaches, Tools, Cost, and More
Link building is the process of earning links from other websites to pages on your site. In SEO, these links...
Pending Home Sales Plunge to Record Low as Mortgage Rates Surge: NAR
By Bill Pan A new report adds to the evidence that rising borrowing costs are weighing heavily on housing demand,...
NY, Feds Raid Programs Suspected of Fraud in New York City
By Zachary Stieber The FBI and state officials launched an operation in New York City on Oct. 20 to crack...
Amazon to Hire 300,000 US Workers for Holiday Season
By Andrew Moran Amazon has posted a help-wanted sign for this year’s holiday season. The online retailer said on Oct....
Trump Launches $25 Million Fraud Whistleblower Program, Offering Cash for Tips
By Emel Akan WASHINGTON—President Donald Trump and Vice President JD Vance announced on Tuesday the launch of a $25 million...
US, Partners Seize Nearly 1,500 Pounds of Cocaine in the Caribbean
By Naveen Athrappully A U.S. task force and foreign partners seized nearly 1,500 pounds of cocaine in two operations in...